Macugen/Visudyne Concomitant Use Appears Safe – Cmte; QLT Wants Trials
Executive Summary
Concomitant use of Pfizer/Eyetech's Macugen (pegaptanib) with Novartis/QLT's Visudyne (verteporfin) does not pose safety concerns, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded Aug. 27
You may also be interested in...
Visudyne Combo Therapies Are QLT’s Focus As Competition Comes Into View
QLT is working to position Visudyne as part of combination therapies for age-related macular degeneration in the face of stiffening competition
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011